Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
ABD646 is an inhibitor of α/β-hydrolase domain-containing protein 18 (ABHD18).1 It reduces ABHD18 activity in a mass spectrometry activity-based protein profiling (MS-ABPP) analysis using a 1:1 mixture of THP-1:COLO 205 cell lysates at 1 and 10 µM. ABD646 reduces the ratio of monolysocardiolipin to cardiolipin (MLCL:CL) in HAP1 tafazzin-knockout cells when used at a concentration of 5 µM. It also reduces the MLCL:CL ratio, improves mitochondrial respiratory chain activity, and improves mitochondrial morphology in skin fibroblasts derived from patients with Barth syndrome, an X-linked disorder associated with mutations in TAFAZZIN. ABD646 (1 µM) improves heart morphology in tafazzin-deficient zebrafish embryos.
WARNING This product is not for human or veterinary use.
1. Genetic suppression features ABHD18 as a Barth syndrome therapeutic target. Nature 645(8082), 1029-1038 (2025).